Relative risk of heavy menstrual bleeding by choice of oral anticoagulant in women aged ≥18 years
| OAC . | Incidence of uterine CRNMB/MB . | Relative risk . |
|---|---|---|
| Warfarin | 4.5%-9.6% | Reference |
| Apixaban | 5.4% | 1.18 |
| Edoxaban | 9.0% | 1.26 |
| Rivaroxaban | 9.5% | 2.10* |
| Dabigatran | 4.7% | 0.53* |
| OAC . | Incidence of uterine CRNMB/MB . | Relative risk . |
|---|---|---|
| Warfarin | 4.5%-9.6% | Reference |
| Apixaban | 5.4% | 1.18 |
| Edoxaban | 9.0% | 1.26 |
| Rivaroxaban | 9.5% | 2.10* |
| Dabigatran | 4.7% | 0.53* |
OAC, oral anticoagulant.
Statistically significant, P < 0.01.